A 67-year-old male with Stage IV non–small cell lung cancer (NSCLC) experienced disease progression following standard-of-care
therapies. A comprehensive circulating tumor DNA (ctDNA) genomic panel failed to identify actionable alterations, leaving no clear
targeted treatment options. Based on clinical trajectory, estimated life expectancy was limited (on the order of months), and care was
approaching a palliative setting.
x